Clinical Trials Logo

Advanced Pancreatic Carcinoma clinical trials

View clinical trials related to Advanced Pancreatic Carcinoma.

Filter by:

NCT ID: NCT04550494 Recruiting - Clinical trials for Metastatic Malignant Solid Neoplasm

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Start date: April 26, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies if talazoparib works in patients with cancer that has spread to other places in the body (advanced) and has mutation(s) in deoxyribonucleic acid (DNA) damage response genes who have or have not already been treated with another PARP inhibitor. Talazoparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. All patients who take part on this study must have a gene aberration that changes how their tumors are able to repair DNA. This trial may help scientists learn whether some patients might benefit from taking different PARP inhibitors "one after the other" and learn how talazoparib works in treating patients with advanced cancer who have aberration in DNA repair genes.

NCT ID: NCT03033225 Completed - Pancreatic Neoplasm Clinical Trials

Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study

Start date: December 6, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well ultrasound-guided verteporfin photodynamic therapy works for the treatment of patients with solid pancreatic tumors that cannot be removed by surgery (unresectable) or pancreatic cancer that has spread to other places in the body (advanced). Photodynamic therapy is a type of laser device that is guided by ultrasound imaging and used in combination with the drug verteporfin that may be less invasive and as effective as current treatment methods for patients with pancreatic cancer.

NCT ID: NCT01454180 Completed - Clinical trials for Advanced Pancreatic Carcinoma

Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets

Start date: October 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the proportion of patients alive after 12 months of the beginning of the trial in patients with advanced pancreatic carcinoma individually selected and grouped according to the expression in tumor tissue for therapeutic targets.